“We are worried and incomprehensible“, declared this Tuesday on France Inter Christèle Gras-Le Guen, head of the pediatrics department at Nantes University Hospital and spokesperson for the French Pediatric Society. The High Health Authority has decided to qualify the medical benefit provided by Beyfortus as “moderate”. This has the effect of having reduced the reimbursement of this preventive treatment against bronchiolitis in babies, passing from 100% last year to only 30% this year. Christèle Gras-Le Guen does not understand this decision since she believes that the effectiveness of Beyfortus “is demonstrated“.
“Last year’s experience was extremely spectacular, with the product’s effectiveness being around 80% in preventing hospitalizations in intensive care, visits to the emergency room, hospitalizations in general, even private consultations.“, she argued. The spokesperson for the French Pediatric Society called for the mobilization of professionals. “This must not be an obstacle so that children from the poorest families are left on the sidelines“, stressed Christèle Gras-Le Guen. “The rest to pay for families” who do not have complementary health insurance “is around 300 euros“, she said. Especially since “several mutual insurance companies do not reimburse or partially reimburse“, she added.
Health
